TERN
NASDAQ · Pharmaceuticals
Terns Pharmaceuticals Inc
$52.86
+2.86 (+5.72%)
Financial Highlights (FY 2025)
Revenue
649.21M
Net Income
208.45M
Gross Margin
67.6%
Profit Margin
32.1%
Rev Growth
-4.4%
D/E Ratio
0.17
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 67.6% | 67.6% | 67.6% |
| Operating Margin | 26.1% | 26.3% | 30.5% |
| Profit Margin | 32.1% | 31.2% | 28.4% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 649.21M | 641.61M | 607.21M |
| Gross Profit | 438.65M | 433.52M | 410.28M |
| Operating Income | 169.34M | 168.77M | 185.24M |
| Net Income | 208.45M | 199.92M | 172.59M |
| Gross Margin | 67.6% | 67.6% | 67.6% |
| Operating Margin | 26.1% | 26.3% | 30.5% |
| Profit Margin | 32.1% | 31.2% | 28.4% |
| Rev Growth | -4.4% | +22.1% | +20.7% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 481.86M | 583.65M | 496.46M |
| Total Equity | 2.77B | 2.41B | 2.51B |
| D/E Ratio | 0.17 | 0.24 | 0.20 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 253.94M | 217.05M | 208.00M |
| Free Cash Flow | 152.21M | 227.98M | 177.76M |